We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Peregrine Post-Market Study for the Treatment of Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02570113
Recruitment Status : Recruiting
First Posted : October 7, 2015
Last Update Posted : January 18, 2018
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The Ablative Solutions, Inc. Peregrine System Infusion Catheter is a catheter-based device which is intended to be used to ablate the afferent and efferent sympathetic nerves serving the kidneys. The catheter is inserted via the femoral artery, steered into the renal artery, and then delivers, by infusion from its distal end, a neurolytic agent. This targets the nerve bundles, which are in the adventitia - a sheath surrounding the artery. The aim is to reduce blood pressure in cases of hypertension, including seriously elevated blood pressure which does not respond to drug treatment. This study will evaluate the safety and performance of the device.

Condition or disease Intervention/treatment
Hypertension Device: Peregrine System Infusion Catheter

Detailed Description:

There is strong evidence in the published literature that the renal nerves are important contributors to hypertension, and that their ablation does not have adverse side-effects.

The literature provides technical, clinical and scientific evidence supporting the use of perivascular renal denervation for a carefully defined patient group.

An existing device (the Medtronic Symplicity catheter) was initially shown to be safe and effective for achieving perivascular renal denervation by delivery of radio-frequency energy. The results of early nonrandomized clinical studies (HTN-1, HTN-2) found that perivascular renal denervation by radio-frequency energy delivery was an effective therapy, associated with very low risks. In other contexts, denervation can also be safely and effectively achieved by neurolytic agents.

The ASI Peregrine System™ Infusion Catheter and the denervation procedure in general is similar enough to the Medtronic Symplicity catheter to enable the use of published data to establish the validity of the design concept of the Peregrine System and estimate the likely levels of risk of side effects. It can be concluded from the literature that the ASI Peregrine System™ will achieve percutaneous renal denervation with a low risk of procedural complications (comparable to accepted percutaneous interventional therapies) and without long-term impairment of renal artery or kidney function or other serious adverse events.

Previous premarket clinical trials have provided support for the safe and effective use of the Peregrine Catheter for the treatment of patients with hypertension. The Peregrine System Infusion Catheter is currently CE marked and the indication for use is "The Peregrine System™ Infusion Catheter is intended for the infusion of a neurolytic agent to achieve a reduction in systemic blood pressure in hypertensive patients." Based upon the literature and previous clinical data, chemical denervation is an appropriate treatment for the specified study population of adults who have hypertension despite taking at least 3 anti-hypertensive drugs of different classes including at least one diuretic.

The objectives of this post-market study are to collect additional safety and performance data pertaining to renal denervation by using dehydrated alcohol as a chemical neurolytic agent delivered into the adventitial/peri-adventitial area of the renal arteries for the purpose of renal denervation, using the Peregrine System™ Infusion Catheter, in patients with hypertension.

In order for the study to be valid, only one chemical neurolytic agent can be used. The Coordinating Investigator has chosen to use dehydrated alcohol (not less than 95% by volume) for therapeutic neurolysis, therefore all participating sites will usethis agent.


Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Post-Market Study of Transcatheter Perivascular Renal Denervation for the Treatment of Hypertension Using the Ablative Solutions Inc. Peregrine System™ Infusion Catheter
Study Start Date : November 2015
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : March 2019
Arms and Interventions

Arm Intervention/treatment
Experimental: Renal Denervation by Neurolysis
Infusion of 0.6 ml of dehydrated alcohol (not less than 95% by volume) into the peri-adventitial space of the renal artery, to achieve renal denervation by neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
Device: Peregrine System Infusion Catheter
The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.


Outcome Measures

Primary Outcome Measures :
  1. Number of Subjects with Treatment Related Adverse Events [ Time Frame: 1-month ]

    The primary safety endpoint is defined by the absence of any of the following events as adjudicated by the CEC through 1-month post procedure:

    1. Peri-procedural major vascular complications;
    2. Major Bleeding as defined by the TIMI Bleeding Classification;
    3. Acute Kidney Injury (AKI) within 1 month of the procedure
    4. Peri-procedural death (within 1 month of the procedure)

  2. Reduction of 24-hour Mean Ambulatory Systolic Blood Pressure [ Time Frame: 6 months ]
    The primary performance endpoint is defined as a reduction of 24-hour mean ambulatory systolic blood pressure following treatment at 6 months, as compared to baseline.


Secondary Outcome Measures :
  1. Proportion of subjects with a decline in eGFR by >25% [ Time Frame: 6 months ]
    Proportion of subjects with a decline in eGFR by >25% from baseline to 6-month follow-up;

  2. Change in serum creatinine [ Time Frame: 6 months ]
    Change in serum creatinine from baseline to 6-month follow-up

  3. New renal arterial stenosis > 60% [ Time Frame: 6 months ]
    New renal arterial stenosis > 60% from the baseline at the 6-month follow-up, to be confirmed by the same imaging method used at baseline.

  4. Proportion of subjects with stroke or Transient Ischemic Attack (TIA) [ Time Frame: 1 month ]
    Stroke or TIA within 1 month of the procedure

  5. Myocardial Infarction (MI) [ Time Frame: 1 month ]
    . Myocardial Infarction (MI) within 1 month of the procedure

  6. Major Adverse Events (MAE) [ Time Frame: 6 months ]

    Major Adverse Events (MAE) through 6-month post-procedure. MAE is defined as the occurrence of any of the following:

    1. All-cause death
    2. End stage renal failure
    3. Significant embolic event resulting in end-organ damage or requiring intervention to prevent it
    4. Major Vascular Complications (including major artery dissections)
    5. Significant new renal artery stenosis (>60% diameter stenosis)
    6. Hypertensive crisis (hypertensive emergency only)
    7. Severe hypotension/syncope

  7. Changes in antihypertensive medications [ Time Frame: 7-day, 1, 3, 6 and 12 months ]
    Changes in antihypertensive medications at 7-day, 1, 3, 6 and 12 months post procedure;

  8. Changes in systolic and diastolic clinic/office blood pressure [ Time Frame: 7-day, 1, 3, 6 and 12 months ]
    Changes in systolic and diastolic clinic/office blood pressure following treatment compared to baseline, assessed at 7-day, 1, 3, 6 and 12 months post-procedure.

  9. Changes in systolic and diastolic 24-hour mean daytime and nighttime ambulatory blood pressure [ Time Frame: 1, 3, 6 and 12-months ]
    Changes in systolic and diastolic 24-hour mean daytime and nighttime ambulatory blood pressure, assessed at 1, 3, 6 and 12-month post-procedure.

  10. Changes in diastolic 24-hour mean ambulatory blood pressure [ Time Frame: 1, 3, 6 and 12-months ]
    Changes in systolic and diastolic 24-hour mean ambulatory blood pressure assessed at 1, 3, 6 and 12-month post-procedure.

  11. Changes in systolic 24-hour mean ambulatory blood pressure [ Time Frame: 1, 3 and 12 months ]
    Changes in systolic 24-hour mean ambulatory blood pressure assessed at 1, 3 and 12 months postprocedure;

  12. Change in eGFR [ Time Frame: 1, 3, 6 and 12 months ]
    Change in eGFR from baseline, to evaluate the progression of Chronic Kidney Disease (CKD) after 1, 3, 6 and 12 months;

  13. The progression of kidney disease [ Time Frame: 1, 3, 6, and 12 months ]
    The progression of kidney disease in subjects with ≤60 mL/min/1.73m2 will be evaluated by comparing the change in eGFR during the study to the historical loss (reduction) of eGFR during the 3 years prior to renal denervation for each individual subject;

  14. Change in albuminuria [ Time Frame: 3, 6, and 12 months ]
    Change in albuminuria from baseline to 3 months post-procedure, with additional assessments at each study time point;

  15. Change in albuminuria categorization [ Time Frame: 3, 6, and 12 months ]
    Change in albuminuria categorization from baseline to 3 months post-procedure, with additional assessments at each study time point;

  16. Change in serum creatinine and cystatin-C [ Time Frame: 3, 6, and 12 months ]
    Change in serum creatinine and cystatin-C from baseline to 3 months postprocedure, with additional assessments at each study time point.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult subject, age 18-80, male or female;
  2. Subject has a target treatment vasculature diameter of ≥4 mm and ≤ 7 mm and length of ≥5 mm;
  3. Subject has 3 measurements with a mean of office Systolic Blood Pressure of

    ≥150 mmHg AND office Diastolic Blood Pressure of ≥85 mmHg;

  4. Subject has a 24-hour mean systolic Ambulatory Blood Pressure Measurement (ABPM) ≥135 mm Hg with ≥70% valid readings (as determined by measurement device);
  5. Subject with hypertension is receiving and adhering to a stable medication regimen of at least 3 anti-hypertensive medications of different classes (for at least 4 consecutive weeks), one of which must be a diuretic;
  6. Subject agrees to have all study procedures performed, to comply with medication regimen and is able and willing to comply with all study follow-up visits;
  7. Subject has provided written informed consent.

Exclusion Criteria:

  1. Subject has a contraindication known for conventional percutaneous interventional procedures such as:

    • intolerance for antiplatelet/anticoagulant therapy
    • known allergy to contrast media
    • bleeding disorders (such as bleeding diathesis, thrombocytopenia and severe anemia)
  2. Subject has documented severe untreated obstructive sleep apnea (Apnea Hypopnea Index [AHI] ≥30 per hour);
  3. Subjects with nephrotic syndrome;
  4. Subjects on immunosuppressive medications or immunosuppressive doses of steroids;
  5. Subject has type 1 diabetes mellitus;
  6. Subject is pregnant or nursing or planning to become pregnant;
  7. Subject has an eGFR ≤20 mL/min/1.73m2

    , based on the CKD-EPI equation;

  8. Subject has imaging-assessed renal artery anatomy abnormalities or variations based on Investigator's evaluation of the screening images [i.e. MRA/CTA examination and/or renal angiography]) meeting one of the following criteria:

    • Renal artery stenosis >60% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment);
    • Any renal artery abnormality or disease that, per the physician assessment, precludes the safe insertion of the guiding catheter (such as but not limited to severe renal artery aneurysm, excessive tortuosity, severe renal artery calcification);
    • Previous renal angioplasty associated with stenting or other implants, that, per the physician's assessment, precludes the safe deployment of the Peregrine catheter components in the target treatment segment of the renal artery;
  9. Subject has a history of nephrectomy, a single kidney or kidney tumor, or urinary tract obstruction (with potential for hydronephrosis);
  10. Subject is known to have a non-functioning kidney or unequal renal size (>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function);
  11. Subject has a renal transplant;
  12. Subject has a history of myocardial infarction, unstable angina pectoris, or stroke/TIA within the last six months from planned procedure;
  13. Subject has hemodynamically significant valvular heart disease;
  14. Subject has heart failure (NYHA III or IV) or has an ejection fraction ≤30%;
  15. Subject with chronic atrial fibrillation;
  16. Subjects who are allergic or intolerant of the neurolytic agent (such as dehydrated alcohol);
  17. Any contraindication to the imaging as required per the protocol;
  18. Subject has a life expectancy of <12 months;
  19. Subject is currently enrolled in other potentially confounding research, i.e., another therapeutic or interventional research trial. Subjects enrolled in observational registries may still be eligible.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02570113


Contacts
Contact: Horst Sievert, MD 0049 46031340 horstsievertmed@aol.com
Contact: Ali Kakavand, PhD +1 650 575 5534 akakavand@ablativesolutions.com

Locations
Belgium
Cliniques Universitaires Saint-Luc Recruiting
Brussels, Belgium, 1200
Contact: Alexandre Persu, MD PhD    +32 2 764 25 33      
Czechia
Na Homolce Hospital Active, not recruiting
Prague, Czechia, 150 30
Germany
Charite-Universitaetsmedizin Berlin Recruiting
Berlin, Germany, 12203
Contact: Maximilian de Bucourt, MD    0049 304 5062 7085      
Universitätsklinik Erlangen Klinik für Nephrologie/Hypertensiologie Recruiting
Erlangen, Germany, 91054
Contact: Roland E Schmieder, Prof.Dr.med.    +49 9131 85 36245      
Elisabeth-Krankenhause Terminated
Essen, Germany, 45138
CardioVasculares Centrum (CVC) Frankfurt Recruiting
Frankfurt, Germany, 60389
Contact: Horst Sievert, MD    0049 46031340      
Universitats-Herzzentrum/University Heart Center Klinik fur Kardiologie und Angiologie Recruiting
Freiburg, Germany, 79106
Contact: Andreas Zirlik, MD    0049 76127034415      
Klinik fur Innere Medizin III Recruiting
Homburg, Germany, 66421
Contact: Felix Mahfoud, MD PhD    +49 6841 16 15911      
Poland
Oddzial Kardiologii Inwazyjnej Active, not recruiting
Tychy, Poland, 43-100
Oddizal Kardiologiczno-Angiologiczny PAKS Active, not recruiting
Ustron, Poland, 43-450
Sponsors and Collaborators
Ablative Solutions, Inc.
Investigators
Principal Investigator: Horst Sievert, MD CardioVasculares Centrum (CVC) Frankfurt
More Information

Responsible Party: Ablative Solutions, Inc.
ClinicalTrials.gov Identifier: NCT02570113     History of Changes
Other Study ID Numbers: CR0001
First Posted: October 7, 2015    Key Record Dates
Last Update Posted: January 18, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases